The mt-atp6 protein is a core component of ATP synthase (Complex V), which catalyzes the final step of oxidative phosphorylation. Specifically:
Proton Translocation: Subunit a facilitates proton movement across the mitochondrial inner membrane, creating a proton gradient .
ATP Synthesis: The energy from proton flow drives the conversion of ADP to ATP via the F1 subunit .
Mutations in mt-atp6 linked to mitochondrial diseases (e.g., Leigh syndrome, NARP) have been studied in yeast systems:
These studies highlight conserved residues critical for subunit a function .
Pathogenic mt-atp6 variants often disrupt ATP synthase assembly or proton channel efficiency, leading to:
ATP Synthesis Deficits: Reduced ATP production due to impaired proton flow .
Mitochondrial Membrane Potential Abnormalities: Increased or decreased membrane potential, reflecting proton leak or channel dysfunction .
For example:
m.8993T>G (p.L156R): Linked to NARP syndrome; causes increased membrane potential and oligomycin resistance .
m.9185T>C (p.L308P): Associated with Leigh syndrome; reduces ATP hydrolysis and impairs complex assembly .
Heteroplasmy Thresholds: Pathogenic variants require high heteroplasmy (>60–80%) to manifest clinically .
Biochemical Heterogeneity: No universal biomarker exists; ATP synthesis rates, membrane potential, and complex assembly vary across mutations .
Therapeutic Targets: Modulating proton flow or enhancing ATP synthase efficiency remains an active research area .
STRING: 99883.ENSTNIP00000000835